Phase II trial showed high overall response rate of 83.3% in richter transformation, indicating promising efficacy of polatuzumab with chemoimmunotherapy.
Key Points
Best overall response rate achieved was 83.3% with a complete remission rate of 50% after treatment with polatuzumab and chemoimmunotherapy.
Patients showed impressive 1 year progression free and overall survival rates of 70.9%, emphasizing treatment's potential efficacy.
Observational analysis in a phase II setting for patients with richter transformation undergoing polatuzumab treatment revealed manageable adverse events profile.
High rates of febrile neutropenia and infections necessitate careful monitoring during treatment, highlighting real-world clinical considerations.